Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Supernus Pharmaceuticals (SUPN)

Supernus Q3 revenue rises 18% to $226.8 million; 2026 revenue guidance raised

Positive Impact 4 of 5 earnings

Supernus reported third-quarter 2026 total revenues of $226.8 million, up 18% from a year earlier, and net earnings of $20.9 million, or $0.35 per diluted share, compared with a net loss of $45.1 million a year earlier. The company raised its full-year 2026 total revenue and GAAP operating earnings guidance, but the guidance will no longer apply if the Indivior merger closes as expected on November 2, 2026.

Key points

  • Q3 2026 net earnings were $20.9 million, or $0.35 per diluted share, versus a net loss of $45.1 million, or $0.80 per share, in Q3 2025.
  • Total revenues were $226.8 million, up from $192.1 million; ONAPGO net sales rose to $17.1 million from $6.8 million.
  • 2026 total revenue guidance was raised to $875 million to $900 million from $860 million to $890 million.
  • The Indivior merger is expected to close November 2, 2026; Supernus common stock is expected to trade under SUPN on November 3, 2026.

The filing

CompanySupernus Pharmaceuticals (SUPN)
Form8-K, current report
Filed with the SECOct 29, 2026, 4:08 PM ET
Accession number0001356576-26-000050

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:18 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.